• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Dr Stuart Goldberg Discusses How COTA Analyzes Oncology Data

Video

Cancer Outcomes Tracking and Analytics (COTA) focuses on stratifying cancer patients by their many subtypes to understand the different treatments, outcomes, and costs for each, according to Stuart Goldberg, MD, chief medical officer, COTA, John Theurer Cancer Center.

Cancer Outcomes Tracking and Analytics (COTA) focuses on stratifying cancer patients by their many subtypes to understand the different treatments, outcomes, and costs for each, according to Stuart Goldberg, MD, chief medical officer, COTA, John Theurer Cancer Center.

Transcript (slightly modified)

Can you provide an overview of COTA (Cancer Outcomes Tracking & Analytics)?

COTA is a data analytics company that has focused on oncology, and really what we’ve understood is that cancer’s not 1 disease. It’s many diseases. So we’ve had to develop a whole new lexicon, a whole new classification system, that stratifies the patients by their individual subtypes. Taking breast cancer from 1 disease to 100s of diseases, because the woman who has HER2/neu positive is very different than the HER2/neu negative, and they have different treatment strategies, different outcomes, and different costs.

By putting all of that information into our system and pulling from the electronic health records, and pulling the unstructured data, the richness of the doctors’ notes, as well as the structured data, like the fields that we fill in like name and date and addresses. By putting all that together and then putting it through a classification system, we can now organize that data so that we can do big data analytics.

Related Videos
Yael Mauer, MD, MPH
Pregnant Patient | image credit: pressmaster - stock.adobe.com
Amit Singal, MD, UT Southwestern Medical Center
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health
Dr Julie Patterson, National Pharmaceutical Council
Diana Isaacs, PharmD
Beau Raymond, MD
Binod Dhakal, MD, Medical College of Wisconsin, lead CARTITUDE-4 investigator
Dr Sophia Humphreys
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.